{"date":"2026-10-10","count":1,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-7878-2026-10-10-1324-1ywt0wy","company_id":"7878","company":"藥祇","market":"興櫃","industry":"生技醫療","date":"2026-10-10","time":"13:24:46","subject":"公告本公司新藥PS1用於第一型糖尿病之美國二期臨床試驗 (IND)申請，已完成美國FDA送件。","clause":"第8款","fact_date":"2026-10-09","cite_as":"公開資訊觀測站重大訊息：藥祇（7878），2026-10-10 13:24，「公告本公司新藥PS1用於第一型糖尿病之美國二期臨床試驗 (IND)申請，已完成美國FDA送件。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}